RESUMEN
We screened a collection of synthetic compounds consisting of natural-product-like substructural motifs to identify a spirocyclic chromane as a novel antiplasmodial pharmacophore using an unbiased cell-based assay. The most active spirocyclic compound UCF 201 exhibits a 50% effective concentration (EC50) of 350 nM against the chloroquine-resistant Dd2 strain and a selectivity over 50 using human liver HepG2 cells. Our analyses of physicochemical properties of UCF 201 showed that it is in compliance with Lipinski's parameters and has an acceptable physicochemical profile. We have performed a limited structure-activity-relationship study with commercially available chromanes preserving the spirocyclic motif. Our evaluation of stage specificities of UCF 201 indicated that the compound is early-acting in blocking parasite development at ring, trophozoite and schizont stages of development as well as merozoite invasion. SPC is an attractive lead candidate scaffold because of its ability to act on all stages of parasite's aexual life cycle unlike current antimalarials.
Asunto(s)
Antimaláricos/química , Antimaláricos/farmacología , Benzofuranos/farmacología , Eritrocitos/parasitología , Malaria/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Compuestos de Espiro/farmacología , Animales , Antimaláricos/síntesis química , Antimaláricos/aislamiento & purificación , Benzofuranos/uso terapéutico , Evaluación Preclínica de Medicamentos , Estadios del Ciclo de Vida/efectos de los fármacos , Malaria/parasitología , Merozoítos/efectos de los fármacos , Merozoítos/crecimiento & desarrollo , Ratones Endogámicos BALB C , Plasmodium berghei , Plasmodium falciparum/crecimiento & desarrollo , Esquizontes/efectos de los fármacos , Esquizontes/crecimiento & desarrollo , Compuestos de Espiro/uso terapéutico , Relación Estructura-Actividad , Trofozoítos/efectos de los fármacos , Trofozoítos/crecimiento & desarrolloRESUMEN
A search for physiological inhibitors of protein phosphatases led to the identification of a Plasmodium falciparum (Pf) cDNA that had the potential to code for an aspartate-rich protein and hence named ARP. The PfARP was virtually identical to its Plasmodium berghei counterpart in gene structure and protein sequence. The PfARP coding sequence contained two introns, and the predicted protein contained 269 amino acid residues. Its primary structure showed significant similarity to eukaryotic proteins of the SET and TAF-family that included two inhibitors of mammalian serine/threonine protein phosphatase 2A (PP2A), namely I1(PP2A) and I2(PP2A). Like the SET and TAF proteins, it had an extremely acidic tail. The cDNA was confirmed by recombinant expression in bacteria. Native parasitic ARP was purified and was found to be highly thermostable. PfARP specifically inhibited the parasitic PP2A at nanomolar concentrations, with no effect on PP1, PP2B, PP5, or PPJ. Expression of PfARP in HeLa cells led to elevated phosphorylation of c-Jun, and activation of transcription factors AP1 and NF-kappa B. These functional properties are also characteristic of the SET/TAF-family proteins. The ARP mRNA and protein were detectable in all the erythrocytic asexual stages of the parasite, and the protein was located mainly in the parasitic cytoplasm. Thus, PfARP is a unique cytoplasmic member of the SET/TAF-family and a candidate physiological regulator of the Plasmodium PP2A.